FOI 2847 2022/23
Anti-VEGF treatments for eye condition
Published 21 September 2023
Anti-VEGF treatments for eye condition
Questions
1. For the 4 months from September to December 2022, how many patients received the following anti-VEGF treatments for any eye condition:
a) Aflibercept
b) Bevacizumab
c) Brolucizumab
d) Dexamethasone
e) Faricimab
f) Ranibizumab - Lucentis
g) Ranibizumab - Ongavia
2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
a) Aflibercept
b) Bevacizumab
c) Brolucizumab
d) Dexamethasone
e) Faricimab
f) Ranibizumab - Lucentis
g) Ranibizumab - Ongavia
Response
1.
|
Drug |
Number_of_patients |
|
a) Aflibercept |
0 |
|
b) Bevacizumab |
61 |
|
c) Brolucizumab |
0 |
|
d) Dexamethasone |
5793 |
|
e) Faricimab |
0 |
|
f) Ranibizumab - Lucentis |
0 |
|
g) Ranibizumab - Ongavia |
0 |
2.
Not doable.